Vectus Biosystems LimitedASX: VBS

Successful Completion of First Group in Phase I Human Trial

· Issued by Vectus Biosystems Limited

Filed with ASX · · 2 pages · English

Vectus Biosystems Limited (Vectus or the Company) is pleased to announce that the first cohort consisting of eight subjects has completed all protocol requirements for the 2mg dose in the Single Ascending Dose (SAD) component of its Phase I/IB trial entitled: “A phase I/Ib, first-time-in-human, single centre, double blind, randomised, placebo-controlled, dose-escalating study of the safety, tolera

Vectus Biosystems Limited on 6ix

Earlier from Vectus Biosystems

Later from Vectus Biosystems

All Vectus Biosystems news releases